the aid library

LIST OPTIONS

Filter

8624

Working for Health 2022-2030 Action Plan: education and employment

World Health Organisation (WHO) (2023) C_WHO

This thematic brief accompanies the Working for Health 2022–2030 Action Plan, serving as a background and rationale to the related actions of the Working for Health progression model (see Annex). The brief aims to inform Member States, nonstate actors and other users of the Action Plan on the con... more

User manual for WHO cervical cancer prevention and control costing tool: HPV vaccination module (‎C4P-HPV tool)

World Health Organisation (WHO) (2023) C_WHO

Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin... more

Ending disease in Africa: vision, strategies and special initiatives, 2023-2030

World Health Organisation (WHO) (2023) C_WHO

While there has been real progress in addressing the burden of disease in the WHO African region, the COVID-19 pandemic has highlighted the link between health, economics and security, as the region saw decades of progress threatened, including positive trends in decreasing inequality. In the Africa... more

Download (165)

View PDF (215)

Malaria action plan for the Eastern Mediterranean Region, 2022-2030

World Health Organisation (WHO) (2023) C_WHO

This action plan is intended for senior-level decision-makers in ministries of health, malaria programme managers, entomologists, and epidemiologists working on malaria and other vectorborne diseases programmes. It is also intended for decision-makers and technical and advocacy staff at other orga... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Report of the workshop for implementing the WHO South-East Asia Regional NCD Roadmap, 2022-2030 WHO

World Health Organization (WHO) World Health Organization (WHO) (2023) C_WHO

The workshop aimed to support countries in the prioritization and acceleration of NCD prevention and management with a specific focus on accelerating the prevention and control of hypertension and diabetes, identifying the most impactful NCD interventions within their context, closing the gaps in ca... more

Country cooperation strategy for WHO and Syrian Arab Republic: 2022-2025

World Health Organization WHO (2024) C_WHO

WHO’s Country Cooperation Strategy (CCS) defines the Organization’s medium-term vision for working in and with a particular country. The CCS, developed in the context of global and national health priorities, examines the overall health situation in a country, including the state of the health s... more

Download (307)

View PDF (219)

Standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) for management of convulsive epilepsy in adults and children

World Health Organization (2012) C_WHO

Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?

National school meals and nutrition strategy 2017–2022

Ministry of Health, Kenya (2018) C1

This strategy takes into account the policies formulated by sectors with cross-cutting interests in school meals, such as education, health, social protection and agriculture.The strategy further complements the provisions of the National School Health Policy and the asso... more

External Link

Pandemics in the age of the Anthropocene: Is ‘planetary health’ the answer?

David P.M., Le Dévédec N. et al. (2021) C2

Some observers have described the coronavirus pandemic as an 'Anthropocene disease,' thereby highlighting its connection with this new ecological era that is characterised by the considerable pressure human activities are exerting on ecosystems and the consequences on public health, society and the ... more

Download (110)

View PDF (164)

Chagas Access: The pilot experience in Colombia

DNDi Latin America (2021) CC

Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th... more

Download (920)

View PDF (1767)

Health Technical Guidelines

ECHO EU (2014)

This guidance is intended to be one stop shop to improve the quality and effectiveness of health interventions in emergency, to respond to the most frequent scenarios and conditions. The main document contains the most common elements to be found in emergencies. As much as possible they are one pag... more

Download (1370)

View PDF (5076)

Integrating severe acute malnutrition into the management of childhood diseases at community level in South Sudan

Emily Keane, Andrea King, Anthony Awira et al. Malaria Consortium South Sudan (2013) C1

Since December 2010, Malaria Consortium has been implementing an innovative approach to community management of severe acute malnutrition, together with an existing integrated community case management (ICCM) programme in South Sudan. This learning paper considers Malaria Consortiums experience of t... more

Download (313)

View PDF (499)

International Development Association Project Paper on a Proposed Additional Gran

International Development Association World Bank (2016) C1

IN THE AMOUNT OF SDR 21.8 MILLION (US$30 MILLION EQUIVALENT) WITH AN ADDITIONAL GRANT FROM THE GLOBAL FINANCING FACILITY (GFF) IN THE AMOUNT OF US$ 10 MILLION TO THE DEMOCRATIC REPUBLIC OF CONGO FOR A HUMAN DEVELOPMENT SYSTEMS STRENGTHENING PROJECT

Health Care Waste Management Policy for Ghana

Ministry of Health Ghana (2020) CC

Ghana's attempt to regulate health care waste management started in 2002 with the development of guidelines on health care waste manage-ment by the Environmental Protection Agency (EPA). In 2006, the Ministry of Health developed the health care waste policy and guidelines. This guidance document im... more

Guidance for laboratories shipping specimens to WHO reference laboratories that provide confirmatory testing for COVID-19 virus

World Health Organization WHO (2020) C_WHO

Interim Guidance 31 march 2020 WHO has established a shipment mechanism to expedite and cover the costs of the shipment of clinical samples from patients with suspected COVID-19 from the country of collection to one of the WHO reference laboratories providing confirmatory molecular testing for COVI... more

Download (1276)

View PDF (6367)

Essential obstetric and newborn care
recommended

Anne-Sophie Coutin, et al. Médecins sans Frontières MSF (2019) C1

Essential obstetric and newborn care is designed as a tool to help protect mothers and their children in adverse environments. It is intended for midwives, doctors with obstetrics training, and health care personnel who deal with obstetric emergencies.

Aufenthaltsgesetz (AufenthG) / Residence Act - English Version
recommended

Federal Ministry of Justice and Consumer Protection; juris GmbH (2008) CC2

Act on the Residence, Economic Activity and Integration of Foreigners in the Federal Territory Residence Act. Translation provided by the Language Service of the Federal Ministry of the Interior. Version information: The translation includes the amendment(s) to the Act by Article 3 of the Act of 6... more

External Link

POSITIVELY PREGNANT

Deutsche AIDS-Hilfe e.V. (2013) C2

This brochure informes HIV postivie pregnant women what they can do for their and their babies health and stresses the importance of a good medical adivce in the beginning of the pregnancy. It is also available in several other languages: http://aidshilfe.de/de/shop/positiv-schwanger-deutsch-eng... more

Download (135)

View PDF (175)

National Action Plan to Tackle Antimicrobial Resistance in the Republic of Tajikistan

Republic of Tajikistan (2018) C_WHO

The present National action plan on antimicrobial resistance (AMR) with component of antimicrobial consumption (AMC) covering both human and agriculture sectors was developed based on the World Health Organization's (WHO) Global plan on AMR dated 2015. With the purpose to develop this plan, in May 2... more

Essential obstetric and newborn care recommended

Aufenthaltsgesetz (AufenthG) / Residence Act - English Version recommended

Essential obstetric and newborn care
recommended

Aufenthaltsgesetz (AufenthG) / Residence Act - English Version
recommended